ARCHIVES

ODAC Votes Against Cell Therapeutics Agent; Requires ChemGenex To Develop Diagnostic.

This article is from The Cancer Letter archive.

Vol. 36 No. 13 | April 9, 2010

Download PDF Visit The Full Archive

Related Articles

In Brief: BRI Gets New FCRF Basic Research Contract; Senate Subcommittee Less Generous Than House

October 2, 1987

Funding Opportunities: NCI extends Deadline for Three RFAs

July 9, 1999

Experts Raise Questions About Influential Swedish Trial Of Mammography Screening.

May 11, 2007

NIH COI Rule Mandates More Disclosure, Leaves Institutions In Charge Of Ethics Of Extramural Researchers

September 16, 2011

Lilly Suspends Phase III Trial Of Tasisulam in Melanoma

January 28, 2011

FDA Approves Taxotere And Gemzar; Sends Approvable Letter For Etopophos

May 24, 1996